Estimate your 10-year risk of developing type 2 diabetes using the validated CANRISK questionnaire.This interactive tool, based on the Diabetes Canada risk assessment model, evaluates key lifestyle and clinical factors to provide a personalized risk score and actionable prevention guidance.
The CANRISK (Canadian Diabetes Risk Questionnaire) is a validated, evidence-based screening tool designed to estimate a person's 10-year risk of developing type 2 diabetes. Developed by Diabetes Canada in collaboration with public health experts, it assesses nine key demographic, anthropometric, and lifestyle factors that are independently associated with diabetes risk. Unlike laboratory tests, CANRISK is non-invasive, self-administered, and can be completed in under five minutes — making it an ideal first-step screening tool in community, workplace, and clinical settings.
The questionnaire was derived from the Framingham Offspring Study and validated using data from the Canadian Health Measures Survey (CHMS). Its scoring algorithm assigns point values to each risk factor, and the total score corresponds to a 10-year risk probability ranging from less than 1% to over 30%. This allows individuals to understand their risk level and take proactive steps toward prevention or early intervention.
Each of the nine CANRISK factors was selected based on robust epidemiological evidence linking it to type 2 diabetes incidence. The scoring system reflects the relative contribution of each factor to overall risk. For example, age is the most heavily weighted factor because diabetes risk increases exponentially with age. Waist circumference and BMI are also heavily weighted due to their strong association with insulin resistance and visceral adiposity.
The CANRISK algorithm uses a logistic regression model to derive the probability of developing diabetes over 10 years. The total score is transformed into a risk percentage using a calibration equation that accounts for the baseline incidence of diabetes in the general population. This approach ensures that the risk estimate is both population-adjusted and individualized.
Risk doubles every decade after age 40. Age-related decline in pancreatic beta-cell function and insulin sensitivity are key drivers.
Waist circumference and BMI measure central obesity, which promotes chronic low-grade inflammation and insulin resistance.
Family history and ethnicity reflect inherited susceptibility. Certain populations have a higher prevalence of diabetes-associated gene variants.
Your CANRISK score falls into one of four risk categories, each with a corresponding 10-year probability of developing type 2 diabetes:
| Risk Category | CANRISK Score | 10-Year Risk | Recommended Action |
|---|---|---|---|
| Low | 0 – 8 | < 1% | Maintain healthy lifestyle. Re-screen in 3–5 years. |
| Moderate | 9 – 15 | ~ 4% | Discuss risk with your doctor. Consider lifestyle modifications. |
| High | 16 – 20 | ~ 17% | Seek medical evaluation. Blood glucose testing recommended. |
| Very High | 21+ | ~ 33% | Immediate medical consultation. Comprehensive diabetes screening advised. |
These risk probabilities are based on population-level data and may vary by individual health status. Always consult a healthcare professional for personalized interpretation.
The Diabetes Prevention Program (DPP) and other landmark studies have shown that type 2 diabetes is largely preventable through lifestyle interventions. Even if your CANRISK score indicates elevated risk, adopting the following evidence-based strategies can significantly lower your chances of developing the disease:
Focus on whole grains, lean proteins, vegetables, and healthy fats. Limit processed foods, refined sugars, and sugary beverages.
Aim for at least 150 minutes of moderate-intensity exercise per week. Walking, cycling, and swimming are excellent choices.
Losing 5–10% of body weight can reduce diabetes risk by up to 58%. Even modest weight loss improves insulin sensitivity.
Type 2 diabetes is one of the most pressing public health challenges of the 21st century. According to the International Diabetes Federation (IDF), approximately 537 million adults (10.5% of the global population) were living with diabetes in 2021 — and this number is projected to rise to 783 million by 2045. Alarmingly, nearly half of all adults with diabetes remain undiagnosed, highlighting the critical need for accessible screening tools like CANRISK.
The economic burden is equally staggering: global health expenditure on diabetes reached US$ 966 billion in 2021, representing a 316% increase over the past 15 years. Early identification of high-risk individuals through screening can reduce these costs by delaying or preventing disease onset, thereby improving quality of life and reducing strain on healthcare systems.